India’s nutraceutical industry is entering a decisive phase of expansion, nearing $24 bn by 2032

Vitafoods India 2026, set for February 11–13, 2026 in Mumbai where over 10,000 trade visitors

India’s nutraceutical industry is entering a decisive phase of expansion, nearing $24 billion by 2032, driven by rising health awareness, preventive care adoption, and evolving consumer expectations that are reshaping nutrition as a cornerstone of everyday healthcare. This rapid growth provides the perfect backdrop for Vitafoods India 2026, set for February 11–13, 2026 in Mumbai where over 10,000 trade visitors, more than 200 exhibitors, and over 40 expert sessions will foster collaboration across ingredient innovation, regulatory clarity, and commercial scale, bridging domestic momentum with global ambitions.

M Krishnamurthy Rao, CMO, Nutraceuticals, Siddhayu Life Sciences, noted that India’s nutraceutical market, currently valued at around $35 billion, is expected to reach $70–75 billion over the next five years, driven by Gen Z’s focus on wellness, transparency, and evidence-based benefits. He highlighted growing demand across cardiometabolic disorders, CNS health, bone and joint health, and women’s health.

Dr Suresh Lakshmikanthan, Chief Business Officer, Natural Remedies, described India as one of the most dynamic nutraceutical growth markets globally. Valued at nearly $15 billion and growing at a CAGR of around 20 per cent, the market is projected to reach $50 billion over the next five years, fuelled by preventive health adoption and demand for clean-label, clinically researched solutions. He also pointed to NBJ reports highlighting Gen Z’s increasing preference for functional foods and beyond-the-pill formats.

Adding another perspective, Saif Mehkri, Director and Founder, Bio-gen Extracts, observed that the industry is shifting from a treatment-first approach to one focused on prevention, performance, and health span. With the market expected to grow at around 10 per cent CAGR and more than double by the early 2030s, he emphasised rising demand for natural, traceable, and consistently performing ingredients.

Ankit Khokhani, CEO, Generex Pharmassist, highlighted the growing demand for evidence-backed solutions, “At Generex Pharmassist, we are redefining how nutraceutical innovation reaches the Indian consumer. By bringing globally patented, clinically proven ingredients and converting them into India-ready, market-winning formulations, we bridge the gap between science and success. At Vitafoods India 2026, we are unveiling next-generation solutions across women’s health, metabolic wellness, sports nutrition and healthy ageing, areas where consumers are increasingly demanding proof rather than promises. As India’s nutraceutical market accelerates toward a value of over USD 30 billion, Generex is committed to shaping a preventive, lifestyle-led future driven by science, transparency and measurable outcomes.”

Jyoti Bhasin, Managing Director, India & Middle East, NSF, said, “India is emerging as a key nutraceutical manufacturing and export hub. Sustaining this momentum requires strong compliance, transparency and product integrity. NSF works with Indian businesses to align local practices with global regulatory expectations. In 2026, NSF is expanding its presence in India in the DS space through the launch of localised protocols for Product certification as well as cGMP program in association with IDMA, these programmes will be based on global best practices, promoting harmonized quality and safety standards as well as meet all local requirements. Vitafoods India 2026 provides a strong platform to introduce these initiatives and build consumer trust at scale.”